CL2023001768A1 - Moléculas de anticuerpos de unión tetravalentes y usos de las mismas - Google Patents
Moléculas de anticuerpos de unión tetravalentes y usos de las mismasInfo
- Publication number
- CL2023001768A1 CL2023001768A1 CL2023001768A CL2023001768A CL2023001768A1 CL 2023001768 A1 CL2023001768 A1 CL 2023001768A1 CL 2023001768 A CL2023001768 A CL 2023001768A CL 2023001768 A CL2023001768 A CL 2023001768A CL 2023001768 A1 CL2023001768 A1 CL 2023001768A1
- Authority
- CL
- Chile
- Prior art keywords
- antibody molecules
- binding antibody
- tetravalent binding
- tetravalent
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127408P | 2020-12-18 | 2020-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001768A1 true CL2023001768A1 (es) | 2024-01-12 |
Family
ID=82058983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001768A CL2023001768A1 (es) | 2020-12-18 | 2023-06-15 | Moléculas de anticuerpos de unión tetravalentes y usos de las mismas |
| CL2025001491A CL2025001491A1 (es) | 2020-12-18 | 2025-05-20 | Moléculas de anticuerpos de unión tetravalentes y usos de las mismas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025001491A CL2025001491A1 (es) | 2020-12-18 | 2025-05-20 | Moléculas de anticuerpos de unión tetravalentes y usos de las mismas |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20250270332A1 (https=) |
| EP (3) | EP4263617A4 (https=) |
| JP (3) | JP7778148B2 (https=) |
| KR (1) | KR20230122077A (https=) |
| CN (2) | CN116917332A (https=) |
| AU (2) | AU2021399278A1 (https=) |
| CA (2) | CA3204321A1 (https=) |
| CL (2) | CL2023001768A1 (https=) |
| IL (2) | IL303344A (https=) |
| MX (1) | MX2023007103A (https=) |
| WO (2) | WO2022130342A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3732201A4 (en) | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | WNT SURROGATES AND THEIR USES |
| CN120025448A (zh) * | 2019-06-11 | 2025-05-23 | 安托拉诊疗公司 | 多价fzd和wnt结合分子及其用途 |
| WO2023250402A2 (en) * | 2022-06-22 | 2023-12-28 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
| WO2023130055A2 (en) * | 2021-12-31 | 2023-07-06 | Surrozen Operating, Inc. | Wnt receptor-specific compound and method relating thereto |
| WO2024007008A2 (en) * | 2022-06-30 | 2024-01-04 | The University Of Chicago | Cd73 (nt5e) targeting polypeptides |
| WO2024227103A1 (en) * | 2023-04-27 | 2024-10-31 | Surrozen Operating, Inc. | Molecules modulating wnt signaling pathways and uses thereof |
| WO2025019458A2 (en) * | 2023-07-14 | 2025-01-23 | The Trustees Of Columbia University In The City Of New York | Specific blood retinal barrier defect in glaucoma directs new treatments and clinical tests |
| WO2025168716A1 (en) | 2024-02-07 | 2025-08-14 | Eyebiotech Limited | Compositions, doses, and methods for treatment of ocular diseases |
| WO2025176847A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Ocular delivery of active agents via microalgae extracellular vesicles |
| US20260092125A1 (en) * | 2024-09-06 | 2026-04-02 | Eyebiotech Limited | Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof |
| WO2026055312A1 (en) * | 2024-09-06 | 2026-03-12 | Merck Sharp & Dohme Llc | Multivalent fzd4, wnt co-receptor, and vegf receptor molecules and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| CN103002911B (zh) | 2008-09-26 | 2015-08-26 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| EP2804629A1 (en) | 2012-01-18 | 2014-11-26 | Genentech, Inc. | Anti-lrp5 antibodies and methods of use |
| DE102012202081A1 (de) | 2012-02-13 | 2013-08-14 | Osram Gmbh | Glühfaden für elektrische lampen und elektrische lampe sowie herstellungsverfahren für einen glühfaden |
| AU2014246658B2 (en) | 2013-04-03 | 2018-10-04 | Peter Maccallum Cancer Institute | Antibodies against human RYK and uses therefor |
| US9237411B2 (en) | 2013-07-25 | 2016-01-12 | Elwha Llc | Systems and methods for providing one or more functionalities to a wearable computing device with directional antenna |
| EP3033356B1 (en) | 2013-08-14 | 2020-01-15 | Sachdev Sidhu | Antibodies against frizzled proteins and methods of use thereof |
| JP6865688B2 (ja) | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| US10919968B2 (en) | 2016-01-29 | 2021-02-16 | Modmab Therapeutics Corporation | Frizzled5 protein-binding agents |
| WO2018026942A1 (en) | 2016-08-02 | 2018-02-08 | Merrimack Pharmaceuticals, Inc. | Heteromeric polypeptides |
| US11039659B2 (en) | 2017-09-07 | 2021-06-22 | Nike, Inc. | Sole structure for article of footwear |
| US20210032352A1 (en) | 2018-02-14 | 2021-02-04 | Antera Therapeutics Inc. | Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof |
| CA3104526A1 (en) * | 2018-07-05 | 2020-01-09 | Surrozen, Inc. | Multi-specific wnt surrogate molecules and uses thereof |
| US10671121B2 (en) | 2018-09-14 | 2020-06-02 | Apple Inc. | Magnetic layout in electronic devices and accessory devices for electronic devices |
| CN120025448A (zh) * | 2019-06-11 | 2025-05-23 | 安托拉诊疗公司 | 多价fzd和wnt结合分子及其用途 |
-
2021
- 2021-12-17 WO PCT/IB2021/061972 patent/WO2022130342A1/en not_active Ceased
- 2021-12-17 MX MX2023007103A patent/MX2023007103A/es unknown
- 2021-12-17 AU AU2021399278A patent/AU2021399278A1/en active Pending
- 2021-12-17 CN CN202180093862.1A patent/CN116917332A/zh active Pending
- 2021-12-17 IL IL303344A patent/IL303344A/en unknown
- 2021-12-17 CA CA3204321A patent/CA3204321A1/en active Pending
- 2021-12-17 EP EP21905972.2A patent/EP4263617A4/en active Pending
- 2021-12-17 AU AU2021404080A patent/AU2021404080A1/en active Pending
- 2021-12-17 EP EP21905973.0A patent/EP4263618A4/en active Pending
- 2021-12-17 CA CA3204322A patent/CA3204322A1/en active Pending
- 2021-12-17 CN CN202180093864.0A patent/CN116964102A/zh active Pending
- 2021-12-17 US US18/267,914 patent/US20250270332A1/en active Pending
- 2021-12-17 IL IL303342A patent/IL303342A/en unknown
- 2021-12-17 KR KR1020237023863A patent/KR20230122077A/ko active Pending
- 2021-12-17 JP JP2023537572A patent/JP7778148B2/ja active Active
- 2021-12-17 JP JP2023537540A patent/JP2024500839A/ja active Pending
- 2021-12-17 WO PCT/IB2021/061971 patent/WO2022130341A1/en not_active Ceased
-
2022
- 2022-06-22 US US17/846,846 patent/US20230118983A1/en active Pending
-
2023
- 2023-06-15 CL CL2023001768A patent/CL2023001768A1/es unknown
- 2023-06-22 EP EP23741240.8A patent/EP4543921A2/en active Pending
- 2023-11-03 US US18/501,589 patent/US20240228631A9/en not_active Abandoned
-
2025
- 2025-05-20 CL CL2025001491A patent/CL2025001491A1/es unknown
- 2025-11-18 JP JP2025197132A patent/JP2026041774A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3204322A1 (en) | 2022-06-23 |
| JP2026041774A (ja) | 2026-03-10 |
| JP2023554500A (ja) | 2023-12-27 |
| US20240132600A1 (en) | 2024-04-25 |
| WO2022130341A1 (en) | 2022-06-23 |
| EP4543921A2 (en) | 2025-04-30 |
| MX2023007103A (es) | 2023-06-27 |
| WO2022130342A4 (en) | 2022-08-11 |
| US20240228631A9 (en) | 2024-07-11 |
| EP4263618A4 (en) | 2024-11-20 |
| US20230118983A1 (en) | 2023-04-20 |
| AU2021404080A1 (en) | 2023-06-29 |
| CA3204321A1 (en) | 2022-06-23 |
| EP4263617A4 (en) | 2025-01-01 |
| EP4263618A1 (en) | 2023-10-25 |
| EP4263617A1 (en) | 2023-10-25 |
| CL2025001491A1 (es) | 2025-08-22 |
| CN116917332A (zh) | 2023-10-20 |
| JP7778148B2 (ja) | 2025-12-01 |
| IL303344A (en) | 2023-08-01 |
| CN116964102A (zh) | 2023-10-27 |
| WO2022130342A1 (en) | 2022-06-23 |
| IL303342A (en) | 2023-08-01 |
| AU2021399278A1 (en) | 2023-06-29 |
| KR20230122077A (ko) | 2023-08-22 |
| JP2024500839A (ja) | 2024-01-10 |
| US20250270332A1 (en) | 2025-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001768A1 (es) | Moléculas de anticuerpos de unión tetravalentes y usos de las mismas | |
| CO2020005981A2 (es) | Anticuerpos anti-tau y uso de los mismos | |
| CL2019001646A1 (es) | Anticuerpos anti-ox40 y sus usos. | |
| CO2018000967A2 (es) | Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador | |
| CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
| UY37123A (es) | Anticuerpos y fragmentos anti-vista, usos de los mismos, y metodos para identificar los mismos | |
| MX2021015439A (es) | Moleculas multivalentes de union a fzd y wnt y usos de las mismas. | |
| MX2022000302A (es) | Moleculas de union que inhiben el crecimiento del cancer. | |
| CL2018003366A1 (es) | Anticuerpos anti -cd40 y sus usos | |
| AR063640A1 (es) | Anticuerpos agonistas de trkb y usos de los mismos | |
| BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
| ECSP17083779A (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos | |
| AR087601A1 (es) | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion | |
| CR20180225A (es) | Anticuerpo anti-tigit y métodos de uso | |
| PA8718601A1 (es) | Anticuerpos anti-5t4 y sus usos | |
| CO2023012821A2 (es) | Anticuerpos anti-nectina-4 y usos de los mismos | |
| MX2022002723A (es) | Receptores de antigeno dimerico (dar) que se enlazan a bcma. | |
| DK3710562T3 (da) | Fremgangsmåde til reformering af methan og lette carbonhydrider til flydende carbonhydridbrændstoffer | |
| CO2019002751A2 (es) | Composiciones marcadoras, y metodos para fabricar y usar las mismas | |
| AR114552A1 (es) | Polipéptidos de unión a ox40 y sus usos | |
| AR073140A1 (es) | Anticuerpos anti-il-23r disenados | |
| MX2023014679A (es) | Peptidos grapados y metodos para su obtencion. | |
| CO2024007117A2 (es) | Proteínas de unión que reconocen al antígeno hpv16 e7 y usos de las mismas | |
| CL2015001939A1 (es) | Nuevos fragmentos de anticuerpos, composiciones y sus usos. | |
| EP4242739A4 (en) | FILM FOR LIQUID CRYSTAL DEVICE, LIQUID CRYSTAL DEVICE AND LIGHT ADJUSTING APPARATUS |